ClinicalTrials.gg
CompletedNCT03287505Updated Dec 29, 2020

Aripiprazole IM Depot for Chinese Patients With Schizophrenia

A Phase 1 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
107th of 125
24 · median 130
Started
2017
with 5 others
Phase 1
13 of 126
none open now
Registered
105th of 126
by date
Lead sponsor
3 of 126
Otsuka Beijing Research Institute

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 107th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2017, is one of 13 in phase 1, and was the 105th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

This study assess pharmacokinetics and safety of single-administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg in patients with schizophrenia.

Read the detailed description

In this study, a single-center, single-dose, single-administration trial will be carried out in patients with schizophrenia diagnosed pursuant to The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), to evaluate pharmacokinetics and safety of single-administration aripiprazole IM Depot (300/400 mg) after its administration in 24 patients with oral tolerance of this drug.

In this study, the washout period before administration is designed as a 35-day duration before administration of the investigational drug (aripiprazoleIM Depot), screening period a 4-week duration (28 days) before administration of the investigational drug, observation period after administration a 20-week duration after administration of the investigational drug and hospital stay a minimum 35-day duration after administration of the investigational drug.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects, and their legal representatives(or their guardian ), who have signed the form(ICF);
  2. Patients with a diagnosis of schizophrenia as defined by (295.30, 295.10, 295.20,295.90 , 295.60);
  3. subjects, both male and female, who are at age between 18 and 64 (also including 18 and 64 years of age) at time of informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have other psychiatric disorders than schizophrenia based on diagnostic criteria of ;
  2. Score of Positive and Negative Syndrome Scale (PANSS): ≥120;
  3. Patients with a complication or a history of diabetic mellitus;
  4. Subjects who are alcoholemia overdependent of drug, or have drug abuse history;

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Abilify IM Depot 300mg by once

    300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;

    Drug: Aripiprazole IM Depot

  • Experimental
    Abilify IM Depot 400mg by once

    400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.

    Drug: Aripiprazole IM Depot

Interventions

  • administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.

    Also known as: ABILIFY MAINTENA

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration

    To assess the maximum Plasma Concentration (Cmax) of aripiprazole and its main metabolite OPC-14857

    Time frame: up to 20 weeks

  2. Time of Maximum Concentration

    To assess the time of Maximum Concentration (tmax) of aripiprazole and its main metabolite OPC-14857

    Time frame: up to 20 weeks

  3. AUC0-∞

    To assess the area under the curve for period of medication, from 0 till infinity (AUC0-∞) of aripiprazole and its main metabolite OPC-14857

    Time frame: up to 20 weeks

  4. Apparent clearance after extravascular administration

    To assess the Apparent clearance after extravascular administration (CL/F) of aripiprazole

    Time frame: up to 20 weeks

Secondary outcomes

  1. Adverse Events

    Adverse events will be examined by frequency, severity, seriousness, discontinuation, and relationship to treatment.

    Time frame: up to 20 weeks

  2. Vital Signs

    Mean change from baseline and the incidence of potentially clinically relevant abnormal values will be calculated for vital signs

    Time frame: up to 20 weeks

  3. Laboratory Examination

    Mean change from baseline and the incidence of potentially clinically relevant abnormal values will be calculated for routine laboratory tests (including prolactin).

    Time frame: up to 20 weeks

Other outcomes

  1. Positive and Negative Symptoms Scale (PANSS)

    To evaluate the change of Positive and Negative Symptoms Scale (PANSS) from baseline.

    Time frame: up to 20 weeks

07

Study locations

1 site
  • Beijing Anding Hospital of Capital Medical University
    Beijing, Beijing 100088, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Nov 2019, 28 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 28 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2017
First posted
Sep 19, 2017
StartActual
Jun 23, 2017
Primary completionActual
Nov 8, 2019
CompletionActual
Nov 8, 2019
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03287505
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
Jun 23, 2017
Primary completion
Nov 8, 2019
Completion
Nov 8, 2019
Last update
Dec 29, 2020

Study contacts

Tao Jiang, Master
principal investigator · Beijing Anding Hospital of Capital Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion